Expansion Of Single-use Endoscopy Will Improve Hospital Efficiency

Key Takeaways

• Expanding single-use endoscopy portfolio and first-mover advantages drive growth by addressing infection concerns and penetrating new clinical segments.
  
• Enhanced manufacturing, distribution, and demographic trends position Ambu for improved margins, recurring sales, and sustained long-term revenue growth.
  
• Reliance on single-use endoscopes amid rising competition, currency risks, and cost pressures exposes Ambu to significant margin and profitability challenges if market or regulatory shifts occur.

Catalysts

A medical technology company, develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide.

• Accelerating adoption of single-use endoscopy solutions due to increasing healthcare focus on infection control and efficiency-Ambu's expanding portfolio (e.g., the SureSight Connect and new urology indications) positions it to capture hospital demand for safer, more efficient procedures, underpinning sustainable revenue growth and potential market share gains.
  
• Ongoing portfolio expansion and first-mover advantages in new segments (e.g., urology, pediatric blades, and complex endoscopy procedures) enable continued penetration of under-served clinical areas-these advances should drive both higher average selling prices and top-line revenue growth over the medium-to-long term.
  
• Scaling of manufacturing capacity (notably the ramp-up of the Mexico facility and ongoing automation/optimization efforts) provides operational leverage-this should allow for improved gross and EBIT margins as volume grows and more products for key markets are sourced closer to customers, offsetting some tariff/FX cost headwinds.
  
• Strengthening distribution and commercial investments, especially in North America (with new leadership and expanding direct sales teams), are expected to support recurring sales and improved pricing control-this positions Ambu for enhanced long-term earnings growth and higher operating leverage as new launches gain traction.
  
• Long-term demographic trends, including an aging global population and the expansion of healthcare infrastructure in emerging markets, are set to increase demand for minimally invasive procedures and single-use devices-Ambu's leadership in these trends supports a positive outlook for sustained revenue growth and eventual margin expansion.

Ambu Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Ambu's revenue will grow by 11.1% annually over the next 3 years.
• Analysts assume that profit margins will increase from 6.0% today to 14.4% in 3 years time.
• Analysts expect earnings to reach DKK 1.2 billion (and earnings per share of DKK 4.51) by about September 2028, up from DKK 359.0 million today.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 35.1x on those 2028 earnings, down from 71.0x today. This future PE is greater than the current PE for the GB Medical Equipment industry at 31.8x.
• Analysts expect the number of shares outstanding to grow by 0.38% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 5.58%, as per the Simply Wall St company report.

Ambu Future Earnings Per Share Growth

Risks

• Heightened currency (FX) volatility and ongoing U.S. dollar depreciation have caused reported revenue growth and margins to fall below organic growth, with future dollar weakness posing a continued risk to both revenue and EBIT margins.
  
• Sustained tariff headwinds from recent global trade changes and shifting geopolitical factors may raise cost of goods sold and sales/distribution expenses, and despite mitigation via Mexico-based manufacturing, these pressures could continue to weigh on net margins and free cash flow over time.
  
• Ambu's business model and top-line growth remain highly dependent on continued penetration of single-use endoscope segments; increased regulatory scrutiny or customer transition to more environmentally friendly/reusable solutions would directly undermine revenue growth and long-term earnings potential.
  
• Intensifying competition within single-use endoscopy from large, established medtech players risks margin compression or delayed sales cycles, especially in newer product segments where Ambu is not a first mover, threatening future revenue growth and profit margins.
  
• Ongoing investments in commercial capacity, R&D, and working capital, driven by the need to maintain operational leverage and support long-term growth, are increasing costs; if revenue momentum slows or fails to meet expectations, these elevated costs could place downward pressure on net margins and profitability.

Valuation

• The analysts have a consensus price target of DKK130.7 for Ambu based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of DKK147.0, and the most bearish reporting a price target of just DKK90.0.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be DKK8.2 billion, earnings will come to DKK1.2 billion, and it would be trading on a PE ratio of 35.1x, assuming you use a discount rate of 5.6%.
• Given the current share price of DKK95.65, the analyst price target of DKK130.7 is 26.8% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.